These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 29689379)

  • 1. Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.
    Selim AG; Moore AS
    J Mol Diagn; 2018 Jul; 20(4):389-397. PubMed ID: 29689379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of minimal residual disease in acute myelogenous leukemia.
    Raanani P; Ben-Bassat I
    Acta Haematol; 2004; 112(1-2):40-54. PubMed ID: 15179004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mind map for managing minimal residual disease in acute myeloid leukemia.
    Benton CB; Ravandi F
    Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introducing minimal residual disease in acute myeloid leukemia.
    Ofran Y; Rowe JM
    Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular biology strategies to detect residual disease.
    Garcés-Eisele J
    Hematology; 2012 Apr; 17 Suppl 1():S66-8. PubMed ID: 22507783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
    Shapiro RM; Kim DDH
    Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
    Yang F; Anekpuritanang T; Press RD
    Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Tools for Diagnosis and Monitoring of AML.
    Guijarro F; Garrote M; Villamor N; Colomer D; Esteve J; López-Guerra M
    Curr Oncol; 2023 May; 30(6):5201-5213. PubMed ID: 37366878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal Residual Disease in Acute Myeloid Leukemia.
    Sung PJ; Luger SM
    Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.
    Yu T; Chi J; Wang L
    Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
    Nunes V; Cazzaniga G; Biondi A
    Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia.
    Bewersdorf JP; Shallis RM; Boddu PC; Wood B; Radich J; Halene S; Zeidan AM
    Blood Rev; 2020 Sep; 43():100650. PubMed ID: 31883804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.
    Mencia-Trinchant N; Hu Y; Alas MA; Ali F; Wouters BJ; Lee S; Ritchie EK; Desai P; Guzman ML; Roboz GJ; Hassane DC
    J Mol Diagn; 2017 Jul; 19(4):537-548. PubMed ID: 28525762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
    Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
    Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them.
    Li SQ; Chen M; Huang XY; Wang H; Chang YJ
    Expert Rev Hematol; 2023; 16(12):981-990. PubMed ID: 37978882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of minimal residual disease in acute myeloid leukemia.
    Kern W; Haferlach C; Haferlach T; Schnittger S
    Cancer; 2008 Jan; 112(1):4-16. PubMed ID: 18000811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations.
    Delsing Malmberg E; Rehammar A; Pereira MB; Abrahamsson J; Samuelsson T; Ståhlman S; Asp J; Tierens A; Palmqvist L; Kristiansson E; Fogelstrand L
    J Mol Diagn; 2019 Jan; 21(1):149-162. PubMed ID: 30273780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.